NDMAC Urges OTC Exclusivity In Canada Similar To U.S. Model
This article was originally published in The Tan Sheet
Executive Summary
Canadian regulators should allow three-year exclusivity for innovations in both existing and new nonprescription drug products, the country's self-care industry trade group says